Clinical trial
Liposomal Doxorubicin in Treating Patients With Liver or Bile Duct Cancer
NCT00003296 · Brown University, Other · Unknown status
Key facts
| NCT number | NCT00003296 |
|---|---|
| Title | Liposomal Doxorubicin in Treating Patients With Liver or Bile Duct Cancer |
| Official title | Phase II Study of TLC D-99 for Hepatobiliary Carcinomas |
| Lead sponsor | Brown University, Other |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer |
| Intervention type | Biological, Drug |
| Interventions | filgrastim, pegylated liposomal doxorubicin hydrochloride |
| Enrollment | 26 |
| Start date | Jan 1, 1998 |
| First posted | Jul 8, 2004 |
| Last update posted | Dec 19, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: